| 44.41 -1.14 (-2.5%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 57.34 | 1-year : | 61.42 |
| Resists | First : | 49.09 | Second : | 52.59 |
| Pivot price | 45.54 |
|||
| Supports | First : | 43.45 | Second : | 36.15 |
| MAs | MA(5) : | 45.03 |
MA(20) : | 46.33 |
| MA(100) : | 49.83 |
MA(250) : | 46.39  |
|
| MACD | MACD : | -1.3 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 24.5 |
D(3) : | 26.9 |
| RSI | RSI(14): 37.7 |
|||
| 52-week | High : | 59.68 | Low : | 30.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SUPN ] has closed above bottom band by 27.8%. Bollinger Bands are 8.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 45.82 - 46.04 | 46.04 - 46.23 |
| Low: | 43.59 - 43.89 | 43.89 - 44.14 |
| Close: | 43.99 - 44.44 | 44.44 - 44.82 |
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Thu, 04 Jun 2026
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - MSN
Wed, 03 Jun 2026
SUPN: Strong CNS portfolio growth, robust financials, and expanding market opportunities ahead - TradingView
Wed, 27 May 2026
Supernus Pharmaceuticals to Participate in June Investor Conferences - GlobeNewswire
Mon, 25 May 2026
SUPN PE Ratio & Valuation, Is SUPN Overvalued - Intellectia AI
Wed, 20 May 2026
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Wed, 20 May 2026
[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 58 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 103.7 (%) |
| Shares Short | 4,730 (K) |
| Shares Short P.Month | 4,730 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.47 |
| Profit Margin | -3.8 % |
| Operating Margin | -3.6 % |
| Return on Assets (ttm) | 1.1 % |
| Return on Equity (ttm) | -2.8 % |
| Qtrly Rev. Growth | 38.5 % |
| Gross Profit (p.s.) | 9.92 |
| Sales Per Share | 13.38 |
| EBITDA (p.s.) | 2.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 83 (M) |
| Levered Free Cash Flow | 133 (M) |
| PE Ratio | -87.08 |
| PEG Ratio | 0 |
| Price to Book value | 2.4 |
| Price to Sales | 3.31 |
| Price to Cash Flow | 30.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|